The US FDA has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg oral formulation of Wegovy ...

Plainsboro, New Jersey Monday, May 5, 2025, 14:00 Hrs [IST] ...

Gold edged higher in Asia amid losses in U.S. stock-index futures. The precious metal's direction is likely to be determined by equities' direction and risk appetite, said Fawad Razaqzada, a market ...

Pop quiz: would you prefer to take a medication as a pill or inject yourself with it? Somehow, I suspect that the vast ...

This report covers recent developments in the health sector, including proposed US federal budget cuts affecting scientific ...

Weight loss pills either reduce appetite, boost metabolism or block fat absorption. Most people lose 5% to 10% of their body ...

Of the total ER visits, nearly 70% involved GI issues, 15% of which led to hospitalization, according to a new study.

Novo Nordisk said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a tense race to get an oral weight-loss medication on the ...

A decision is expected in the fourth quarter of 2025.

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.